Evaluation of Tc-99m(V) DMSA for imaging inflammatory lesions: an experimental study.
The present study evaluated 99mTc(V) DMSA as an agent for the visualization of inflammatory lesions in comparison to 99mTc(III) DMSA and 99mTC-HIG. All three radiopharmaceuticals were prepared with commercial kits. 99mTc(V) DMSA was prepared at neutral pH by the addition of first bicarbonate and then pertechnetate to the kit contents. The labeling efficiency was 99% as determined by ITLC. Abscesses were induced by i.m. injection of 50 microliters turpentine into the right thighs of 36 Swiss albino mice. Six days later 3.7 MBq of each radiopharmaceutical was i.v. administered to 12 mice. The mice were sacrificed at 1, 3, 6 and 24 h later. Scintigrams were obtained with a gamma camera. The abscesses were better visualized on scintigrams with 99mTc(V) DMSA compared to 99mTc(III) DMSA, starting at 1 h. The animals were dissected and the organs were removed, weighed and the radioactivity determined with a gamma counter. The abscess to other tissue ratios were higher with 99mTc(V) DMSA than the other radiopharmaceuticals. The max. abscess/muscle ratios were 9.46 +/- 3.20 (24 h), 4.19 +/- 1.39 (6 h) and 5.98 +/- 1.17 (24 h) and max. abscess/blood ratios were 6.22 +/- 1.41, 4.09 +/- 0.84 and 0.914 +/- 0.351 all at 24 h for 99mTc(V) DMSA, 99mTc(III) DMSA and 99mTc-HIG, respectively. Experimental arthritis was produced in New Zealand white rabbits by intra-articular injection of ovalbumin. Four days later 37 MBq of 99mTc(V) DMSA and 99mTc-HIG were each i.v. administered to 3 rabbits. Scintigrams obtained at 1, 3, 6, and 24 h clearly demonstrated arthritic joints. ROI's over arthritic joints were compared to contralateral normal joints (A/C). The max. A/C ratios were 2.10 +/- 0.31 (3 h) and 2.92 +/- 0.99 (24 h) for 99mTc(V) DMSA and 99mTc-HIG, respectively. Our results indicated the feasibility of imaging inflammatory lesions with 99mTc(V) DMSA.
Ercan
M T
MT
Department of Nuclear Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Gülaldi
N C
NC
Unsal
I S
IS
Aydin
M
M
Peksoy
I
I
Hasçelik
Z
Z
D000038:Abscess / Q000000981:diagnostic imaging; D000818:Animals; D001168:Arthritis / Q000000981:diagnostic imaging; D005069:Evaluation Studies as Topic; D007136:Immunoglobulins / Q000378:metabolism; D007249:Inflammation / Q000000981:diagnostic imaging*; D051379:Mice; D015609:Organotechnetium Compounds / Q000493:pharmacokinetics; D011817:Rabbits; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D004113:Succimer / Q000493:pharmacokinetics; D013667:Technetium / Q000493:pharmacokinetics; D019783:Technetium Tc 99m Dimercaptosuccinic Acid; D014018:Tissue Distribution
D007136:Immunoglobulins; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; C065376:technetium Tc 99m immunoglobulin; D019783:Technetium Tc 99m Dimercaptosuccinic Acid; D013667:Technetium; D004113:Succimer